Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CRPOF: Pursuant to the Plan of Arrangement Aeterna Zentaris acquired all of the issued and outstanding common shares of Ceapro Inc. Ceapro shareholders received 0.02360 of an Aeterna share for each Ceapro share held.
Ceapro Inc.
7824 – 51 Avenue
Edmonton, AB T6E 6W2
Canada
780-421-4555
http://www.ceapro.com
Ceapro Inc., a biotechnology company, develops, commercializes, and markets health and wellness products, and technology relating to plant extracts in Canada, the United States, Germany, and other countries. Its products comprise natural active ingredients, including beta glucan, avenanthramides, oat powder, oat oil, oat peptides, and lupin peptides that are marketed to personal care, cosmetic, medical, and animal health industries through its distribution partners and direct sales; and veterinary therapeutic products, such as an oat shampoo, an ear cleanser, and a dermal complex/conditioner for veterinarians in Japan and Asia. The company’s products and technologies under research and development, or pre-commercial stage include a platform using its beta glucan formulations to deliver compounds for treatments in the personal and healthcare sectors; an extension to the active ingredients product range; various novel enabling technologies, including Pressurized Gas Expansion drying technology; new oat variety and technologies to enhance the content of avenanthramides; and CeaProve, a diabetes test meal to screen pre-diabetes and to confirm diabetes diagnosis. Ceapro Inc. was incorporated in 1997 and is headquartered in Edmonton, Canada.